aDivision of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA ...

A glimmer of hope may be on the horizon for a ruthless cancer that former Sen. Ben Sasse (R-Neb.) once called a “definite death sentence.” An experimental treatment from Revolution Medicines helped ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Pancreatic cancer is one of the most challenging diseases to treat, and while survival rates have improved since the 1970s, they have plateaued in recent years. But two promising drugs in the pipeline ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen. Ben Sasse this week said he's taking daraxonrasib.

Former Sen. Ben Sasse (R-Neb.) detailed his battle with cancer and reflected on his life during a wide-ranging interview with The New York Times’s Ross Douthat. The conversation, released Thursday as ...